The EMA’s human medicines committee refused marketing approvals for two drugs from Neuraxpharm and Apellis at its January meeting, but both companies have said they will a
Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended
UCB’s efforts to build a franchise of therapies for muscle-wasting disease generalised myasthenia gravis have taken another step forwards after the CHMP recommended approv
GSK is on the brink of EU approval for JAK inhibitor momelotinib as a treatment for myelofibrosis patients with anaemia, after the EMA’s human medicines committee issued a
Swiss biotech Santhera is on the brink of its first regulatory approval for Duchenne muscular dystrophy treatment vamorolone, after getting a positive opinion on the drug
Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea